Zeripatamig Biosimilar Bispecific Antibody (CD47 × CD19) for Research

Cat No.: GMP-Bios-INN-1474

Anti-IAP/CD47 therapeutic antibody (Pre-made Zeripatamig biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Zeripatamig (development code TG-1801) is a bispecific monoclonal antibody targeting CD47. It is developed by TG Therapeutics for B-cell lymphoma, Chronic lymphocytic leukaemia in Phase I development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1474-1mg 1mg
GMP-Bios-INN-1474-10mg 10mg
GMP-Bios-INN-1474-100mg 100mg
GMP-Bios-INN-1474-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Zeripatamig biosimilar, Bispecific mAb, Anti-IAP/CD47;CD19 Antibody: Anti-CD47/Leukocyte surface antigen CD47/Antigenic surface determinant protein OA3/Integrin-associated protein (IAP) therapeutic antibody
INN Name Zeripatamig
Target IAP/CD47;CD19
Format Bispecific mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1;G1
VD LC Kappa;Lambda
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Discontinued
100% SI Structure 8rp8:AB:HL;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2022
Year Recommended 2023
Companies TG Therapeutics
Conditions Approved na
Conditions Active na
Conditions Discontinued B-cell lymphoma;Chronic lymphocytic leukaemia
Production na
Development Tech na